Heartflow, an AI-powered cardiac diagnostic company backed by Bain Capital, raised $316.7 million in its upsized IPO, targeting a valuation up to $1.5 billion. The company priced 16.6 million shares at $19 each on August 8, 2025. This successful offering marks a revival in the medtech IPO market, supported by Heartflow's strong financial performance, innovative AI technology for coronary artery disease assessment, and expanded insurance coverage from major payers like UnitedHealthcare. Industry experts note the company's high growth potential while cautioning about market volatility.